Congress Combatting PBMs Perverse Incentives to Keep Costs High – DC Journal – InsideSources

A review of prescription drug formularies last year revealed that a $10,000 brand drug for prostate cancer was preferred on a formulary, while its $450

Read the full article here

Related Articles